In addition, since HIF-1α is a transcription factor that facilitates both malignant and normal cell adaptation to hypoxic stress in the internal environment, it is particularly important to design drugs targeting only HIF-1α expressed in tumours to reduce the adverse effects. The gene discussed is HIF1A; the disease is neoplasm.